PHG News & Events

Backs FY26 adjusted EBITDA margin view 12.5%-13%. Backs FY26 free cash flow view EUR 1.3B-1.5B. The company said, "Philips 2026 outlook includes currently known information, including tariffs, within an uncertain macro environment. It excludes any potential International Emergency Economic Powers Act tariff refunds. It excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice."

Reports Q1 revenue EUR 3.91B vs. EUR 4.1B last year. The company said, "We delivered a good start to 2026, with strong order intake growth at 6%, comparable sales growth of 4% and margin expansion of 40 basis points, reflecting disciplined execution against our plan in an uncertain macro-environment. Sales grew across segments and was led by North America and Europe. We are moving forward with full energy on our new plan to accelerate profitable growth, built on three strategic pillars: focused segment-specific strategies, differentiated platform-based innovations, and disciplined execution. We are proud to remain the number one MedTech patent applicant in Europe and to have secured regulatory approval for key AI-powered innovations such as SmartHeart, which automates cardiac MR imaging planning in one click. Our unique, differentiated platforms drove strong demand by combining hardware, software and AI. DeviceGuide gained regulatory approval, adding AI-powered real-time guidance to complex cardiac procedures on the Azurion image-guided therapy platform. Our OneBlade grooming platform resonated with customers by providing superior experience and versatility in use. Disciplined execution underpins our progress as we navigate an increasingly dynamic macro-environment. In response to external pressures, we are focused on what we can control: stepping up productivity actions to offset the impact of tariffs and higher cost inflation, keeping our savings plans on track, and further strengthening our supply chain. At the same time, we are intensifying commercial and service excellence to reach more customers and consumers through our innovations. With quality at the heart of our operations, our entire team is dedicated to delivering better care for more people."

Philips announced it has received 510 clearance from the FDA for its Rembra platform of scanning systems, including Rembra CT, Rembra RT and Areta RT. The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency, and access to high-quality imaging. As imaging volumes and clinical complexity continue to rise, healthcare providers need solutions that can help them work more efficiently while maintaining confidence in clinical decisions.

Royal Philips announced it has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral CT Verida system. "With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets," said Dan Xu, Business Leader of CT at Philips. "By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways."